Business Update & Financial Outlook

Broad and innovative pipeline to solve significant unmet medical needs Phase 2 Oncology MK-0482 NSCLC MK-2870 Neoplasm Malignant MK-4830 CRC WELIREG (MK-6482) Biliary MK-7684A (vibostolimab MK-1308 (quavonlimab) KEYTRUDA (MK-3475) Melanoma Esophageal Certain VHL tumors (EU) +pembrolizumab) CRC Biliary NSCLC Advanced Solid Tumors NSCLC Endometrial Bladder Prostate Ovarian Esophageal Breast MK-1308A RCC HCC Cervical MK-3543 (quavonlimab SCLC Pancreatic CRC (bomedemstat) +pembrolizumab) Rare Cancers Endometrial Myeloproliferative CRC MK-5684 Esophageal Disorders HCC Prostate TUKYSA (MK-7119) Gastric Melanoma MK-4280 Advanced Solid Tumors HCC SCLC (favezelimab) MK-5890 (boserolimab) Bladder HNSCC NSCLC NSCLC Biliary MK-2140 (zilovertamab SCLC Cervical Hematological Malignancies Ovarian vedotin) MK-4280A Endometrial Bladder (favezelimab+pembroli LYNPARZA (MK-7339) Prostate Gastric Breast zumab) Advanced Solid Tumors NSCLC Gastric Bladder LENVIMA (MK-7902) SCLC Hematological Malignancies Esophageal Biliary NSCLC Ovarian Pancreas Melanoma RCC SCLC Pancreas Prostate Oncology Phase 3 KEYTRUDA (MK-3475) CSCC (EU) Hepatocellular (EU) Mesothelioma Ovarian SCLC MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308A (quavonlimab +pembrolizumab) RCC MK-7684A (vibostolimab +pembrolizumab) Melanoma LENVIMA (MK-7902) Esophageal Gastric HNSCC NSCLC LYNPARZA (MK-7339) NSCLC SCLC WELIREG (MK-6482) RCC Oncology Under regulatory review KEYTRUDA (MK-3475) 2L HCC (US) LA Merkel Cell (US) Adjuvant NSCLC (EU) HER2+ Gastric (EU) Resectable NSCLC (US, EU) 1L HER2- Gastric (US, EU, JPN) 1L Biliary (US, EU, JPN) LYNPARZA (MK-7339) Metastatic 1L Prostate (JPN) General medicine TUKYSA (MK-7119) Breast CRC Gefapixant (MK-7264) Cough (US, EU) MK-3475A NSCLC (pembrolizumab SCLC +hyaluronidase) NSCLC MK-4280A (favezelimab +pembrolizumab) V940 CRC Melanoma Hematological Malignancies Vaccines V181 Dengue Virus Infectious diseases MK-8591B (islatravir+MK-8507)¹ HIV-1 Infection MK-8591D (islatravir+lenacapavir)² HIV-1 Infection Cardiovascular MK-0616 Hypercholesterolemia MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3Available in the US under EUA 4Development is co-funded by Royalty Pharma 5Requested re-examination of EU MAA following CHMP major objection of data to support market authorization General medicine MK-1942 Treatment Resistant Depression MK-6024 (efinopegdutide) NASH Neuroscience MK-81894 Schizophrenia Immunology MK-7240 Ulcerative Colitis Infectious diseases MK-8591A (doravirine+islatravir)² HIV-1 Infection LAGEVRIO (MK-4482)³ COVID-19 antiviral Vaccines MK-1654 (clesrovimab) V116 Respiratory Syncytial Virus (RSV) adult Pneumococcal vaccine, Cardiovascular MK-7962 (sotatercept) Pulmonary Arterial Hypertension 29 As of August 2, 2023

View entire presentation